Role of IL-6 trans-signaling in CCl4 induced liver damage  by Gewiese-Rabsch, Jessica et al.
Biochimica et Biophysica Acta 1802 (2010) 1054–1061
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isRole of IL-6 trans-signaling in CCl4 induced liver damage
Jessica Gewiese-Rabsch, Claudia Drucker, Sven Malchow, Jürgen Scheller, Stefan Rose-John ⁎
Institute of Biochemistry, Christian-Albrechts-University of Kiel, Kiel, Germany⁎ Corresponding author. Department of Biochemistry,
zu Kiel, Olshausenstraße 40, D-24098 Kiel, Germany. Tel.
431 880 5007.
E-mail address: rosejohn@biochem.uni-kiel.de (S. Ro
0925-4439/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbadis.2010.07.023a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 May 2010
Received in revised form 20 July 2010
Accepted 29 July 2010
Available online 3 August 2010
Keywords:
Interleukin-6
Carbon tetrachloride
Liver damage
Regeneration
IL-6 trans-signalingInterleukin-6 (IL-6) plays an important role in liver regeneration and protection against liver damage. In
addition to IL-6 classic signaling via membrane bound receptor (mIL-6R), IL-6 signaling can also be mediated
by soluble IL-6R (sIL-6R) thereby activating cells that do not express membrane bound IL-6R. This process
has been named trans-signaling. IL-6 trans-signaling has been demonstrated to operate during liver
regeneration. We have developed methods to speciﬁcally block or mimic IL-6 trans-signaling. A soluble
gp130 protein (sgp130Fc) exclusively inhibits IL-6 trans-signaling whereas an IL-6/sIL-6R fusion protein
(Hyper-IL-6) mimics IL-6 trans-signaling. Using these tools we investigate the role of IL-6 trans-signaling in
CCl4 induced liver damage. Blockade of IL-6 trans-signaling during CCl4 induced liver damage led to higher
liver damage, although induction of Cyp4502E1 and thus bioactivation of CCl4 was unchanged. Depletion of
neutrophils resulted in reduced liver transaminase levels irrespective of IL-6 trans-signaling blockade.
Furthermore, IL-6 trans-signaling was important for reﬁlling of hepatocyte glycogen stores, which were
depleted 24 h after CCl4 treatment. We conclude that IL-6 trans-signaling via the soluble IL-6R is important
for the physiologic response of the liver to CCl4 induced chemical damage.Christian-Albrechts-Universität
: +49 431 880 3336; fax: +49
se-John).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Interleukin 6 (IL-6) is an inﬂammatory cytokine with additional
functions outside the immune system. Two different pathways have been
described for IL-6. In the classical IL-6 pathway, IL-6 binds to its speciﬁc
Interleukin-6-receptor (IL-6R) and the IL-6/IL-6R complex binds to the
transducing receptor glycoprotein 130 (gp130) leading to homodimer-
ization and subsequent activation of the STAT3 pathway. IL-6R is only
expressed on somecells,mainly onhepatocytes and leukocytes.However,
IL-6 can also signal via soluble IL-6R (sIL-6R) that is generated via
proteolytic cleavage or, in humans also via alternative splicing. This
alternative pathway, which enlarges the range of IL-6 target cells, is called
IL-6 trans-signaling [1,2].
Using transgenic mice we have shown that the IL-6/sIL-6R complex
(i.e. activation of IL-6 trans-signaling) but not IL-6 alone was capable to
inducehepatocyteproliferationeven in theabsenceof liverdamage.Using
gene deﬁcientmice itwas shown that IL-6 plays an important role in liver
regeneration [3,4]. We developed Hyper-IL-6, a fusion protein of IL-6
bound to the sIL-6Rwhichmimics IL-6 trans-signaling [5]. In vivo, Hyper-IL-6, but not IL-6 alone, induced hepatocyte proliferation after hepatec-
tomy or D-galactosamine induced liver damage, demonstrating the
potential of IL-6 trans-signaling to accelerate liver regeneration [6–8].
IL-6 trans-signaling can speciﬁcally be blocked by a soluble
gp130Fc fusion protein (sgp130Fc) without affecting IL-6 signaling
via the membrane bound IL-6R [9]. This sgp130Fc protein was used to
demonstrate that endogenous IL-6 trans-signaling was important for
chronic inﬂammation states [10,11] and colon cancer [12]. Recently,
we could demonstrate that sgp130Fc reduced glycogen consumption
in the liver of animals treated with D-galactosamine [13].
CCl4 is a hepatotoxin that causes direct hepatocyte damage by altering
the permeability of cellular, lysosomal and mitochondrial membranes
[14]. Furthermore, CCl4 is metabolized by the cytochrome P450-
dependent monooxygenase Cyp450 2E1 forming the reactive CCl3* and
Cl3COO* radicals, which can covalently bind to proteins, lipids and nucleic
acids and thus induce liver damageand initiate lipidperoxidation [15–17].
Recently, it has been shown that CCl4 not only causes primary liver
necrosis, but also hepatocyte apoptosis [18].
IL-6 deﬁcient mice were shown to be more sensitive to CCl4 damage.
Interestingly, this effect could not be compensated by recombinant IL-6
but only by Hyper-IL-6 indicating a role of IL-6 trans-signaling in the
response to CCl4 liver damage [19].
In the present study we focus on the role of IL-6 trans-signaling in
response to liver injury causedbyCCl4. Byblockingendogenous IL-6 trans-
signalingwedemonstrate for theﬁrst time the importance of the sIL-6R in
response to chemically induced liver damage.
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2.1. Animals and CCl4 treatment
Male C57Bl/6 N mice were kept at a 12-h light-dark cycle under
standard conditions and provided with food and water ad libitum.
Sgp130 transgenic animals were generated [20] and treated identically
to C57Bl/6 N for ﬂow cytometric analysis of neutrophils. For all
experiments 4–6 mice per groupwere used. Liver damage was induced
by intraperitoneal injection (i.p.) of CCl4 (Sigma, Deisenhofen,
Germany) dissolved in rape oil (20% v/v) immediately before treatment
and applied as one dose of 3 ml/kg body weight. All experiments were
performed according to the German guidelines for animal care and
protection (V 31272241.121-3 (41-3/06)).
2.2. Treatment and quantiﬁcation of sgp130Fc levels via Enzyme-linked
immunoabsorbent assays
Mice were treated i.p. with 250 μg sgp130Fc 18 h prior to CCl4
treatment. sgp130Fc levels were measured via Enzyme-linked
immunoabsorbent assays (ELISA) in the serum of the mice as
described [20] using a human gp130 Elisa Kit (DuoSet human gp130
ELISA Kit, R&D Systems, Wiesbaden, Germany) according to the
manufacturer's instructions. Serum was diluted 1:2,000 in 1% BSA/
PBS and measured in duplicates. Recombinant gp130 was used as
standard.
2.3. Induction of IL-6 trans-signaling with Hyper-IL-6
Mice were treated with 4 μg Hyper IL-6 [5] i.p. 18 h prior to CCl4
treatment.
2.4. Neutrophil depletion
As described previously [20], neutrophils were depleted using a
puriﬁed rat anti-mouseLy6G/Ly6C monoclonal antibody (mAb) (BD
Bioscience, Heidelberg, Germany). Mice were injected with 100 μg
mAb i.p. 18 h prior to CCl4. Depletion was controlled with stainings of
neutrophils on parafﬁn tissue sections as described below.
2.5. Flow cytometric analysis
20 μl ofwholebloodsampleswereused for FACSanalysis,whereby the
mABs Ly6GC (BD Biosciences, Heidelberg, Germany) and CD11b (BD
Biosciences, Heidelberg, Germany) were used to count inﬁltrating
neutrophils. Immediately, blood was transferred into 100 μl FACS EDTA
buffer (2 mM EDTA in PBS) to prevent clotting and inverted brieﬂy. For
each staining 100 μl of blood/ EDTA buffermixturewas transferred into a
well of a 96-well-plate. To block Fc-receptors on, the suspension was
incubatedwithmouse Fc Block CD 16/32 mAb (BD Biosciences). The cells
were subsequently treated with the ﬂuorescence coupled mAbs for
30 min. Thereafter96-well-platewascentrifugedat1500 rpmfor5 minat
4 °C, supernatantwas discarded and pelletwas immediately resuspended
in 100 μl 1×FACS Lysing solution (BD Biosciences). Wells were washed
twicewith 100 μl FACS buffer (PBS, 1%BSA, 1 g/LN3Na) and resuspended
in 200 μL PBS and analyzed by FACS (FACSCanto; Becton Dickinson,
Heidelberg, Germany). In general, data were acquired from 10,000 gated
events per sample.
2.6. Serum alanine aminotransferase, serum aspartate aminotransferase,
potassium and uric acid measurements
Serum alanine aminotransferase (ALT), serum aspartate amino-
transferase (AST), potassium and uric acid were determined using a
Reﬂotron analyzer (Roche Diagnostics, Basel, Switzerland) and Reﬂo-tron test strips. These parameters were determined in diluted blood
sera.
2.7. Soluble IL-6R serum concentrations
sIL-6R levels were measured via ELISA using a murine IL-6R ELISA
Kit (DuoSet murine IL-6 ELISA Kit, AF1830, R&D Systems, Wiesbaden,
Germany) according to the manufacturers instructions. Serum was
diluted 1:10 in 1% BSA/PBS and measured in duplicates. Recombinant
mouse IL-6R was used as standard.
2.8. IL-6 serum concentrations
IL-6 levels were measured via enzyme-linked immunoabsorbent
assays using a murine IL-6 ELISA Kit (DuoSet murine IL-6 ELISA Kit,
DY406, R&D Systems, Wiesbaden, Germany) abiding to the manu-
facturers instructions. Serum was diluted 1:10 in 1% BSA/PBS and
measured in duplicates. Recombinant mouse IL-6 was used as
standard.
2.9. Protein preparation and Western blotting
Livers were homogenized in lysis buffer (500 mM NaCl, 50 mM Tris,
pH7.4; 0.1% SDS, 1% NP-40) and Western blots were performed as
described previously [13]. 40 μg of protein in 5x Laemmli buffer was
applied onto SDS-polyacrylamide gels, electrophoretically separated, and
transferred onto PVDF-membranes. After blocking in Tris buffered saline
(TBS, 0.3 M NaCl, 0.05 M Tris) with 0.05% Tween and 5% skim milk,
membranes were incubated with primary antibodies overnight at 4 °C.
Primary antibodies were diluted 1:1,000 in blocking solution. The
following mAbs were used: pSTAT3, STAT3, β-Actin (Cell Signaling,
Boston, USA) and Cyp2E1 (Abcam, Cambridge, UK). Thereafter, mem-
branes were washed and incubated with horseradish-coupled secondary
antibodies (AmershamBioscience, Buckinghamshire, U.K.) at a dilution of
1:5,000. Signals were visualized using enhanced chemiluminescence
detection system (ECLplus Amersham-Biosciences, Buckinghamshire, U.
K.). The membranes were exposed to the Image reader LAS-100 Pro
system (Fujiﬁlm, Düsseldorf, Germany) or X-ray-ﬁlms (Amersham-
Biosciences, Buckinghamshire, U.K.).
2.10. Tissue processing, immunohistochemistry, Tunel staining
Liver tissue was ﬁxed in 4% formaline, processed and immunos-
tained. Staining for Apoptosis was carried out using a Peroxidase in
Situ Apoptosis Detection Kit (Chemicon International, Billerica, USA).
The signal was developedwith DAB Substrate (3,3' Diaminobenzidine,
Dako, Glostrup, Denmark) and samples were counterstained with
methylgreen (Serva, Heidelberg, Germany).
2.11. HE and DAPI staining
Tissue sections were shortly incubated in Gill3 Hematoxylin
(Thermo Scientiﬁc, Cheshire, UK), differentiated in 0.5% acetic acid,
rinsed in tapwater and stainedwithGiemsa's azur eosinmethyleneblue
solution (Merck, Darmstadt, Germany). Necrotic areas were quantiﬁed
using ImageJ-Software. Necrotic areas were calculated from 30 random
high-powered ﬁelds of three mice and given in percent of total area.
Tissue sectionswere stainedwithDAPI (4',6-Diamidino-2-phenylindole
dihydrochloride) (Sigma,Deisenhofen,Germany) diluted1:1,000 in PBS
for 10 min.
2.12. Periodic Acidic Schiff (PAS) staining
Glycogen was stained within the liver with PAS stainings as
described previously [13]. Shortly, tissue sections were incubated in
0.8% periodic acid (Sigma, Deisenhofen, Germany) followed by an
Fig. 1. Serum levels of soluble IL-6Receptor (sIL-6R) after CCl4 induced liver damage.
C57Bl/6 N mice were injected i.p. with a single dose of 3 ml/kg BW of a 20% (v/v) CCl4
solution (black bars) or mock treated (white bars). Serum levels of sIL-6R were
measured by ELISA at the indicated time points. sIL-6R levels were signiﬁcantly
increased direct (Pb0.0001), 24 h (Pb0.005) and 48 h (Pb0.0001) after CCl4 treatment.
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Sections were counterstained with Shandon Gill3 Hematoxylin
(Thermo Scientiﬁc, Cheshire, UK).
2.13. 5-bromo-2-deoxyuridine (BrdU) staining
Two hours prior to sacriﬁce, micewere injected with 0.1 μg/g body
weight (bw) BrdU. Positive cells were visualized immunohistochemi-
cally. Staining for BrdU was carried out using a mouse BrdU mAb
(Vector Laboratories, CA) diluted in sample diluent (Dako, Glostrup,
Denmark). After incubation with labeled polymer-HRP-anti-mouse
mAb (Dako envision, Glostrup, Denmark), the signal was developed
with AEC Substrate (Dako, Glostrup, Denmark). Samples were
counterstained with Shandon Gill3 Hematoxylin (Thermo Scientiﬁc,
Cheshire, UK).
2.14. Preparation of microsomes
Mice liverswere homogenized in 10 mMKH2PO4, pH 7.4, containing
0.25 M sucrose, 1 mMEDTA, 0.1% (w/v) BSA and 1 mMDTT at 4 °C. The
homogenate was centrifuged at 750g for 15 min and the supernatant
was again centrifuged until the pellet remained pale (normally 3–5
centifugation steps). The pellet was discarded. Subsequently the
supernatant was centrifuged at 10,300g for 20 min. The pellet was
discarded and the supernatant was centrifuged at 137,000g for 70 min.
The supernatantwasdiscarded and thepelletwas resuspended inbuffer
and centrifuged again at 137,000g for 70 min. The ﬁnal pellet was
resuspended in buffer and stored at −80 °C. Samples were taken for
measuring protein concentration using the BCA Kit (Pierce, Rockford,
IL). Equal amounts of protein were analyzed withWestern blot analysis
using a polyclonal CYP2E1 antibody (Abcam, Cambridge, UK) as
described above.
2.15. Thiobarbituric acid reactive substances (TBARS) quantiﬁcations
TBARS were used as an index of the extent of lipid peroxidation
[21]. 1 mg liver tissue homogenate (100 μl) was mixed with 200 μl ice
cold 10% (w/v) trichloroacetic acid to precipitate proteins. After
incubation (15 min on ice) and centrifugation (2200g, 15 min, 4 °C)
200 μl supernatant was mixed with equal volume 0.67% (w/v)
thiobarbituric acid (TBA) and incubated for 10 min at 100 °C. After
cooling, the lipid peroxidation product malondialdehyde (MDA) was
measured at 532 nm using 1,1,3,3-tetramethoxypropane as standard.
3. Results
3.1. Upregulation of sIL-6R upon CCl4 induced liver damage
Acute liver damage was induced with a single injection of 3 ml/kg
body weight of a 20% (v/v) CCl4 solution. Serum levels of sIL-6R as
measured by ELISA were signiﬁcantly elevated after CCl4 treatment. As
shown in Fig. 1, amore than two-fold increase in endogenous sIL-6R levels
was observed directly after damage induction. Elevated sIL-6R levelswere
maintained throughout 48 h, indicating that IL-6 trans-signaling was
induced upon liver damage by CCl4 treatment.
3.2. Quantiﬁcation of CCl4 induced liver damage
Liver damage after CCl4 treatment was quantiﬁed by measuring
serum ALT and AST levels (Fig. 2A, B). To speciﬁcally block IL-6 trans-
signaling, mice were injected with 250 μg sgp130Fc i.p. per mouse
18 h before CCl4 treatment. Serum levels of sgp130Fc levels ranged
between 35-55 μg/ml as veriﬁed by ELISA measurements and
therefore were shown to be high enough to inhibit the activity of
the IL-6/sIL-6R complexes [20,22] throughout the course of the
experiment (Suppl. Fig. 1). Treatment of the mice with the designercytokine Hyper-IL-6 led to no signiﬁcant changes in serum ALT levels
as compared to CCl4 treatment alone. It should be noted, however,
that Hyper-IL-6 was only injected once 18 h prior to CCl4 treatment.
Since the half-life of Hyper-IL-6 is in the range of 24 h, little of the
cytokine would be expected to be left in the circulation after 48 h. We
therefore believe that in order to rigorously test a beneﬁcial effect of
Hyper-IL-6 during liver damage, experiments with daily injections of
Hyper-IL-6 protein or with genetic delivery via an adenovirus [8]
should be performed.
CCl4 treatment increased ALT and AST levels after 24 and 48 h. When
IL-6 trans-signaling was blocked by injection of recombinant sgp130Fc
protein, ALT andAST levels increased dramatically after 24 h and elevated
levelsweremaintained at 48 h. Injection of Hyper-IL-6 resulted in a slight
decreaseof liverdamage inducedbyCCl4 treatmentafter48 h.Histological
examination of the overall liver damage 48 h after CCl4 administration
showed smaller necrotic areas in CCl4 treatedmice compared to sgp130Fc
pretreated mice (Fig. 2C, a, b, c, d). Quantiﬁcation of liver damage 48 h
after CCl4-induced liver damage indicated that only 33.2% of the liver was
necrotic in CCl4 treated mice compared to 58.6% in sgp130Fc pretreated
mice (Fig. 2E). No signiﬁcant difference was seen in the number of
apoptotic nuclei as measured by TUNEL staining (Fig. 2C, e, f). Using DAPI
staining, we noted less intact nuclei and extended necrotic areas in
sgp130Fc pretreated animals (Fig. 2C, g, h). The reduction of DAPI positive
hepatocytes is shown in Fig. 2D. Interestingly, after 6 and 24 h, IL-6 levels
were signiﬁcantly higher in sgp130Fc pretreated mice as compared to
control animals (Suppl. Fig. 2). These results indicated that endogenous IL-
6 trans-signaling was protective after CCl4 treatment.
3.3. Quantiﬁcation of oxidative damage
Thiobarbituric acidic reactive substances (TBARS) are indicators of
lipid peroxidation. TBARS were elevated in liver tissues of sgp130Fc
treated animals 4 and 6 h after CCl4 treatment (Fig. 3A). This
enhancement of lipid peroxidation could be reversed when mice were
treated with Hyper-IL-6 prior to CCl4 (data not shown). Moreover, after
CCl4 treatment, uric acid and potassium levels in the blood were
elevated upon sgp130Fc treatment and lowered upon Hyper-IL-6
treatment (Suppl. Fig. 3). Since uric acid and potassium are markers
for oxidative and general cell damage [23] these data conﬁrm that
oxidative cell damage is higher when IL-6 trans-signaling is blocked.
3.4. Expression levels of Cyp2E1 in the livers of CCl4 treated mice
Liver damage by CCl4 depends on biotransformation catalyzed by
cytochrome P450 2E1 (Cyp2E1). To measure protein expression levels
Fig. 2. CCl4 induced liver damage increaseswhen IL-6 trans-signaling is blocked. C57Bl/6 Nmicewere injected i.p.with a single doseof sgp130Fc toblock IL-6 trans-signalingbefore treatedwith
CCl4. (A) ALT and (B) AST were measured in blood serum 24 and 48 h after CCl4 treatment. ALT (Pb0.0001) and AST (Pb0.05) levels were signiﬁcantly higher when IL-6 trans-signaling was
blockedwith sgp130Fc. (C)Histological evaluations of liver sections 48 hafter CCl4 injection. (a)Hematoxylin–eosin stainings (10-foldmagniﬁcation) of CCl4 only and (b) of sgp130Fcpretreated
mice. Thedamagedarea is circled forquantiﬁcationwith the ImageJ-Software. (c)Hematoxylin–eosin stainings (20 foldmagniﬁcation)ofCCl4onlyand(d)of sgp130Fcpretreatedmice, (e)Tunel
stainings (20 foldmagniﬁcation) of CCl4 only and (f) of sgp130Fc pretreatedmice, (g)DAPI stainings (40 foldmagniﬁcation) of CCl4 only and (h) of sgp130Fc pretreatedmice. Damagewasmore
severe in sgp130pretreatedanimals, but theoccurrenceof apoptotic events is comparable. (D)QuantiﬁcationofHEstainings showmorenecrotic area (circled ina, b) in sgp130Fcpretreatedmice
(Pb0.005) when compared to CCl4 treated mice. (E) Quantiﬁcation of Tunel stainings show comparable apoptotic events in sgp130Fc pretreated and CCl4 treatedmice. (F) Evaluation of DAPI
stainings show that more nuclei are intact in CCl4 treated animals in comparison to sgp130Fc pretreated animals (Pb 0.0001).
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Fig. 3. Quantiﬁcation of oxidative damage. (A) Evaluation of oxidative stress by TBARS
quantiﬁcation. TBARSweremeasured in total protein lysates 0, 2, 4 and 6 h after intoxication
with CCl4. Values were signiﬁcantly increased in sgp130Fc pretreatedmice (grey bars) 4 and
6 h post CCl4 injection when compared to CCl4 only treatedmice (Pb0.05). (B)Western blot
for Cyp2E1 of microsomal preparations 48 h post CCl4 injection.
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carried out. Fig. 3B shows that protein expression of Cyp2E1 was
strongly induced 24 and 48 h after CCl4 treatment as compared to 6 h
after CCl4 treatment. This is interesting since in a recent publication,
Horiguchi and coauthors showed that upon CCl4 treatment of mice,
CYP2E1 expression was markedly downregulated at 6 and 12 h post
CCl4 treatment [24]. Notably, treatment of the animals with sgp130Fc
did not affect protein levels of Cyp2E1. Therefore, higher liver damage
in sgp130Fc treatedmice did not result from different Cyp2E1 levels in
the liver.
3.5. gp130 signaling in sgp130Fc treated animals
Treatment of mice with CCl4 led to activation of the STAT3
pathway after 2 h with a peak after 4 h as measured by phosphor-
ylation of STAT3 (Fig. 4A). Treatment of the mice with the sgp130Fc
protein resulted in a strong reduction in phosphorylated STAT3
protein in CCl4-treated mice. Interestingly, only partial blockade of
STAT3 activation was achieved by sgp130Fc treatment indicating that
gp130 on liver cells was also stimulated via the membrane bound IL-
6R upon after CCl4 treatment. It should be noted that treatment of
mice with sgp130Fc alone did not affect phosphorylation of the STAT3
protein. Liver cell proliferation was quantiﬁed by BrdU staining. 2 h
prior to sacriﬁce, mice were injected with BrdU and liver sections
were analyzed immunohistochemically. Quantiﬁcation of positive
cells revealed that liver cell proliferation depended at least in part onsignaling via IL-6/sIL-6R, since a blockade of this pathway signiﬁ-
cantly reduced the number of proliferating cells (Fig. 4B).
3.6. Role of neutrophils in CCl4 damaged livers
It has been documented that the presence of neutrophils has an
impact on liver damage in different models including CCl4 induced
liver damage [25]. To determine the role of neutrophils after CCl4
damage, we depleted neutrophils in control and sgp130Fc pretreated
mice prior to CCl4 injection and investigated the impact of neutrophil
depletion on the severity of liver damage. Mice were treated with anti
Ly-6G mAb 18 h before CCl4 injection and sacriﬁced 24 h after the
insult. Depletion of neutrophils resulted in reduced ALT levels in CCl4
injected mice irrespective of sgp130Fc pre-treatment (Fig. 5). Al-
though sgp130Fc pretreatment led to higher ALT levels in the absence
or presence of neutrophils, the difference in ALT levels between
neutrophil depleted and non-depleted animals was similar in
sgp130Fc untreated and treated mice, indicating that part of the
liver damage observed in CCl4 treated animals was caused by
neutrophils although they do not explain the observed higher damage
in the sgp130Fc treatment group.
3.7. Impact of IL-6 trans-signaling on glycogen content within the liver
CCl4 exposure leads to activation of glycogen phosphorylase, and
causes glycogen depletion in the liver [26,27]. As shown in Fig. 6, no
glycogen was detectable in liver sections 24 h after liver damage. 48 h
after treatment, glycogen was restored in the livers of CCl4 treated
animals, whereas sgp130Fc pretreated mice showed very little
glycogen in the liver. These ﬁndings indicate that IL-6 trans-signaling
has a signiﬁcant impact on glycogen metabolism after CCl4 induced
liver damage.
4. Discussion
In the present study we show that the response of the liver to an
acute CCl4 insult is strongly inﬂuenced by IL-6 trans-signaling via the
sIL-6R. Early after CCl4 treatment, sIL-6R levels were signiﬁcantly
increased. The protein sgp130 is a natural, speciﬁc inhibitor of IL-6
trans-signaling [9] and we have developed a sgp130Fc fusion protein,
which blocks IL-6 trans-signaling without affecting classical IL-6
signaling via the membrane bound IL-6R [28]. In this study we show
that blockade of the IL-6 trans-signaling pathwaywith sgp130Fc leads
to an increase in state levels of IL-6 at early time points after the
injury. This increase in IL-6 might be explained by the increased half-
life of IL-6 prolonged by the formation of sgp130F/sIL-6R/IL-6
immune complexes. A similar effect has been found after the
administration of IL-6R neutralizing antibodies to patients with
rheumatoid arthritis and Castleman disease [29].
In gene deﬁcient mice it has been shown that CCl4 mediated
damage was more severe in the absence of IL-6 [19,30]. We now
demonstrate that liver damage is increased when only IL-6 trans-
signaling is blocked. Different parameters of liver damage were
quantiﬁed. Serum ALT and AST levels were found to be signiﬁcantly
higher in the presence of the sgp130Fc protein. Increased liver
damage was also visible morphologically in HE stainings showing
massive necrotic areas. DAPI stainings showed less intact nuclei than
in livers of control mice, indicating necrotic tissue damage.
An additional aspect of CCl4 induced liver injury is the induction of
inﬂammation and oxidative damage. Oxidative stress is commonly
quantiﬁed via the amount of lipid peroxidation in liver tissue. In the
present study we show increased lipid peroxidation when IL-6 trans-
signaling was blocked. Similar results were obtained in IL-6 deﬁcient
mice [19]. Other parameters for oxidative stress or common cell
damage are uric acid and potassium, which play a critical role in
antioxidant defense and lipid peroxidation in human blood plasma
Fig. 4. STAT3 phosphorylation and liver cell proliferation is impaired in mice with blocked IL-6 trans-signaling. (A)Western blots showing that STAT3 phosphorylation was impaired
when IL-6 transsignaling was blocked by sgp130Fc as compared to mice treated with CCl4 only. (B) Quantiﬁcation of western blots show reduced STAT3 phosphorylation 4 h after
CCl4 injection in sgp130Fc pretreated mice. (C) Quantiﬁcation of BrdU stainings of liver section 48 h after CCl4 injection showing less BrdU-positive nuclei in sgp130Fc pretreated
mice (grey bars) when compared to mice treated with CCl4 only (black bars) (Pb0.0001).
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blocked indicating that this signaling pathway is important in the
defense of the body to oxidative stress.
Investigating possible explanations for these observations we
focused on the impact of inﬁltrated neutrophils within the liver.
Recently it was found that in a kidney damage model, the number of
inﬁltrating neutrophils and the tissue damage was lower in IL-6
deﬁcient mice [32]. For CCl4 induced liver damage it was found that
neutrophils participate in CCl4 induced liver damage, which was
reduced upon depletion of neutrophils [25]. We have demonstrated
before that less inﬁltrating neutrophils were detected in acute
inﬂammation when the IL-6 trans-signaling pathway was blocked
[20,22]. In CCl4 induced liver damage we conﬁrmed that depletion of
neutrophils before CCl4 treatment reduced the liver damage.
However, in sgp130Fc pretreated mice, ALT levels and other markers
of liver damage were higher than in CCl4 treated animals, whereas
neutrophil levels remained unchanged. We therefore hypothesize
that the effect of IL-6 trans-signaling on the extent of the induced liver
damage is not dependent on neutrophils.
It should be noted that pretreatment with sgp130Fc very likely
may have reduced STAT3 activation not only in the liver but may also
in immune cells such as macrophages and neutrophils. Inhibition of
STAT3 in macrophages and neutrophils may therefore account for theincreased IL-6 levels because in a recent study, myeloid speciﬁc STAT3
conditional knockout had resulted in elevated IL-6 levels after CCl4
treatment as compared to wildtype mice [24].
24 h after CCl4 treatment glycogen within the liver was consumed
but was replenished 48 h after CCl4 treatment. However, when IL-6
trans-signaling was blocked, glycogen replenishment was signiﬁcant-
ly delayed. Interestingly, we have recently noted that glycogen
consumption was blocked 24 h after D-galactosamine damage in
sgp130Fc transgenic mice underlining the different mechanism of
liver damage by CCl4 [13].
In earlier reports we have demonstrated the potential of the IL-6/sIL-
6R complex to induce liver regeneration [6–8]. In the present study, we
show that the concentration of sIL-6R increased after CCl4 administration.
Furthermore, by blocking endogenous IL-6 trans-signaling we demon-
strate that this pathway is important for the response of the liver to
chemical damage. Importantly, the role of STAT3 has most recently been
addressed in two elegant studies using conditional gene ablation [24,33].
The authors showed that hepatocyte speciﬁc STAT3 knockout in mice
resulted in enhanced liver injuryupon treatmentof themicewithCCl4 but
decreased liver regeneration in response to partial hepatectomy ablation
[24,33]. These studies clearly demonstrated that the role of STAT3 in the
response of the liver to injury anddamage is complex.Moreover, it should
be noted that other gp130-induced signaling pathways such as the AKT
Fig. 5. Blockade of IL-6 trans-signaling is independent of neutrophils. (A) Neutrophils
were depleted with the anti-Ly6G/Ly6C monoclonal antibody before CCl4 injection.
Liver damage was quantiﬁed via serum ALT levels 24 h post CCl4 treatment. ALT values
were signiﬁcantly reduced in the sera of neutrophil depleted animals (Pb0.005). (B)
Quantitative blood ﬂow cytometric analysis of neutrophils in percent at the indicated
time points after CCl4 induced liver damage was carried out in C57Bl/6 N mice treated
with CCl4 after previous injection of sgp130Fc or mock treatment. (C) Quantitative
blood ﬂow cytometric analysis of neutrophils in percent at the indicated time points
after CCl4 induced liver damage was performed in C57Bl/6 N and sgp130Fc transgenic
mice treated with CCl4.
Fig. 6. Glycogen staining in livers upon CCl4 damage. PAS staining of liver sections 24
and 48 h after CCl4 induced liver damage showed decelerated glycogen restoration in
sgp130Fc pretreated animals 48 h after CCl4 injection when compared to mice treated
with CCl4 only. (a) CCl4 only 24 h and (b) CCl4 only 48 h post CCl4. (c) sgp130Fc
pretreated 24 h and (d) sgp130Fc pretreated 48 h post CCl4. (e) Mock (oil only) treated
for 24 h and (f) 48 h.
1060 J. Gewiese-Rabsch et al. / Biochimica et Biophysica Acta 1802 (2010) 1054–1061pathway may also be important for the integrity of the liver upon injury
and damage. Since IL-6 neutralizing strategies have been approved for the
clinic in Europe and the US for the treatment of inﬂammatory diseases, it
will be important to monitor, which activities of IL-6–when blocked–
might prove harmful to the organism.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2010.07.023.Acknowledgements
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